| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Clinical |
Authors' Affiliations: Divisions of 1 Hematology-Oncology and 2 Cardiology, Department of Internal Medicine; 3 Colleges of Pharmacy and Medicine; and 4 Center for Biostatistics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Requests for reprints: Manisha H. Shah, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210. Phone: 614-293-8629; Fax: 614-293-3112; E-mail: manisha.shah{at}osumc.edu.
Purpose: This phase II study was undertaken to assess objective response and toxicity of histone deacetylase inhibitor depsipeptide in patients with neuroendocrine tumors.
Experimental Design: A total of 15 patients with metastatic neuroendocrine tumors received a 4-hour i.v. infusion of depsipeptide at 14 mg/m2 on days 1, 8, and 15 every 28 days. Tumor response was assessed at 8-week intervals using Response Evaluation Criteria in Solid Tumors. Most patients were chemo-naïve (n = 12) but receiving long-acting octreotide for carcinoid syndrome (n = 11). All patients had Eastern Cooperative Oncology Group performance status of 0 to 1.
Results: The study was terminated prematurely due to an unexpected high number of serious cardiac adverse events so the objective response rate could not be determined. A total of 77 doses of depsipeptide with a median of four doses (range, 2-13) per patient were administered. The most common adverse events included nausea (86%), anorexia (73%), vomiting (66%), and fatigue (73%). A sudden death attributed to possible fatal ventricular arrhythmia occurred within 24 hours after the fifth dose of depsipeptide. Furthermore, asymptomatic grade 2 ventricular tachycardia (n = 2) and prolonged QTc (n = 3) probably related to depsipeptide were observed. Plasma depsipeptide levels measured in a subset of patients failed to reveal differences among patients with or without cardiac adverse events.
Conclusions: Depsipeptide was associated with a high number of potentially serious cardiac adverse events in patients with metastatic neuroendocrine tumor. As sudden death possibly associated with depsipeptide was observed in this trial, the risks for potentially life-threatening arrhythmia associated with this agent need to be comprehensively evaluated.
Commentary
Clin. Cancer Res. 2006 12: 3871-3874.
This article has been cited by other articles:
|
|
 |
|
  H. Su, L. Altucci, and Q. You Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors Mol. Cancer Ther., May 1, 2008; 7(5): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Klimek, S. Fircanis, P. Maslak, I. Guernah, M. Baum, N. Wu, K. Panageas, J. J. Wright, P. P. Pandolfi, and S. D. Nimer Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes Clin. Cancer Res., February 1, 2008; 14(3): 826 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, D. Lebwohl, E. Masson, G. Laird, M. R. Cooper, and H. M. Prince Clinically Relevant QTc Prolongation Is Not Associated With Current Dose Schedules of LBH589 (panobinostat) J. Clin. Oncol., January 10, 2008; 26(2): 332 - 333. [Full Text] [PDF]
|
|
|
|
|
|
E. L. Strevel and L. L. Siu In Reply J. Clin. Oncol., January 10, 2008; 26(2): 333 - 334. [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, E. Kruchin, et al. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin Clin. Cancer Res., January 1, 2008; 14(1): 188 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Strevel, D. J. Ing, and L. L. Siu Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero New drug development in digestive neuroendocrine tumors Ann. Onc., August 1, 2007; 18(8): 1307 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Molife, P. Fong, M. Scurr, I. Judson, S. Kaye, and J. de Bono HDAC Inhibitors and Cardiac Safety Clin. Cancer Res., February 1, 2007; 13(3): 1068 - 1068. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Shah, M. A. Villalona-Calero, G. Marcucci, J. C. Byrd, and M. R. Grever HDAC Inhibitors and Cardiac Safety Clin. Cancer Res., February 1, 2007; 13(3): 1068 - 1068. [Full Text] [PDF]
|
|
|
|
|
|
E. H. Rubin, N. G.B. Agrawal, E. J. Friedman, P. Scott, K. E. Mazina, L. Sun, L. Du, J. L. Ricker, S. R. Frankel, K. M. Gottesdiener, et al. A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7039 - 7045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Bates, D. R. Rosing, T. Fojo, and R. L. Piekarz Challenges of Evaluating the Cardiac Effects of Anticancer Agents. Clin. Cancer Res., July 1, 2006; 12(13): 3871 - 3874. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
